Summary: NeuroKaire’s new CLIA-certified lab launches a pharmacogenetic assay analyzing 95 variants across 24 genes, empowering tailored treatments for psychiatric, neurological, and related conditions.
Takeaways:
- Precision Medicine for the Brain: NeuroKaire’s pharmacogenetic test helps healthcare providers personalize treatment for mental health, neurological disorders, pain, and sleep conditions by analyzing genetic variations.
- Advanced Testing Capabilities: The assay covers 132 drugs and evaluates 95 genetic variants, ensuring comprehensive insights for optimizing medication efficacy and safety.
- Commitment to Quality: CLIA certification ensures NeuroKaire’s lab meets rigorous standards for accuracy and reliability, supporting its mission to advance evidence-based care in psychiatry and neurology.
NeuroKaire, a pioneering biotechnology company specializing in precision medicine in psychiatry and neurology, announced its Kearny, NJ-based laboratory has been certified by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical testing.
Precision Medicine for Central Nervous System Disorders
NeuroKaire’s new CLIA laboratory’s first offering is a pharmacogenetic assay focused on psychiatric and neurological drugs. Pharmacogenetics is the study of the interaction between genetic variations and drug response.
The comprehensive test analyzes 95 variants across 24 genes and covers 132 drugs that are indicated for mental health states, various neurological diseases, as well as pain and sleep medications. By analyzing genetic variations, the test enables healthcare providers to tailor medications and treatment plans based on the genetics of each patient. This milestone marks a significant step forward in NeuroKaire’s commitment to advancing precision medicine and improving patient care in central nervous system disorders, the company says.
“We are excited about obtaining CLIA certification for our lab, as a key milestone in implementing precision medicine for the brain,” says Daphna Laifenfeld, PhD, co-founder and chief strategy officer at NeuroKaire. “CLIA certification reflects the rigorous quality standards met by our laboratory testing, demonstrating accuracy, reliability, and precision. This is the first step in our vision to help advance the fields of psychiatry and neurology by providing patient-specific, evidence-based insights to physicians.”
